levodopa has been researched along with alloxan in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdeen, S; Chapman, E; Chitre, S; Hoang, QQ; Johnson, SM; Park, Y; Ray, AM; Salim, N; Sivinski, J; Stevens, M; Washburn, A | 1 |
| Benedetti, MS; Dostert, P; Frigerio, E | 1 |
| Birkmayer, W | 1 |
3 other study(ies) available for levodopa and alloxan
| Article | Year |
|---|---|
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
Topics: Biological Products; Chaperonin 10; Chaperonin 60; Escherichia coli; Humans; Inhibitory Concentration 50; Protein Folding; Rafoxanide; Salicylanilides; Suramin | 2019 |
Effect of L-dopa, oxyferriscorbone and ferrous iron on in vivo lipid peroxidation.
Topics: 2,3-Diketogulonic Acid; Alloxan; Animals; Antioxidants; Ascorbic Acid; Drug Combinations; Ethane; Ferric Compounds; Iron; Levodopa; Linolenic Acids; Lipid Peroxidation; Male; Rats; Rats, Inbred Strains | 1991 |
Milestones in the development of modern Parkinson therapy.
Topics: 2,3-Diketogulonic Acid; Alloxan; Behavior; Bromocriptine; Drug Combinations; Drug Therapy, Combination; Ferric Compounds; Humans; Levodopa; Neurology; Parkinson Disease; Selegiline; Tryptophan | 1987 |